Dataset from A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1 (DESTINY-Breast01)
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/00007153
下载链接
链接失效反馈官方服务：
资源简介：
Some human epidermal growth factor receptor 2 (HER-2) breast cancer patients do not respond
or become resistant to current treatment. DS-8201a is a new experimental product that is a
combination of an antibody and a drug. It has not yet been approved for use. DS-8201a may
slow down tumor growth. This might improve outcomes for these patients.
创建时间：
2026-03-03
